NeuroPace, Inc. (NPCE): Price and Financial Metrics


NeuroPace, Inc. (NPCE): $1.61

0.06 (+3.87%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NPCE POWR Grades

  • NPCE scores best on the Value dimension, with a Value rank ahead of 72.78% of US stocks.
  • The strongest trend for NPCE is in Value, which has been heading up over the past 116 days.
  • NPCE's current lowest rank is in the Momentum metric (where it is better than 10.51% of US stocks).

NPCE Stock Summary

  • NPCE has a higher market value than just 12.4% of US stocks; more precisely, its current market capitalization is $48,561,135.
  • NPCE's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.52 -- higher than only 4.68% of US-listed equities with positive expected earnings growth.
  • NEUROPACE INC's stock had its IPO on April 22, 2021, making it an older stock than merely 5.37% of US equities in our set.
  • If you're looking for stocks that are quantitatively similar to NEUROPACE INC, a group of peers worth examining would be PAR, SPIR, LEDS, SOPH, and BASE.
  • NPCE's SEC filings can be seen here. And to visit NEUROPACE INC's official web site, go to www.neuropace.com.

NPCE Valuation Summary

  • NPCE's EV/EBIT ratio is -3.5; this is 146.05% lower than that of the median Healthcare stock.
  • NPCE's price/sales ratio has moved down 11.8 over the prior 19 months.

Below are key valuation metrics over time for NPCE.

Stock Date P/S P/B P/E EV/EBIT
NPCE 2022-11-01 1.7 1.3 -1.7 -3.5
NPCE 2022-10-31 1.7 1.4 -1.7 -3.5
NPCE 2022-10-28 1.7 1.4 -1.7 -3.5
NPCE 2022-10-27 1.6 1.3 -1.6 -3.4
NPCE 2022-10-26 1.6 1.3 -1.6 -3.4
NPCE 2022-10-25 1.8 1.5 -1.8 -3.6

NPCE Price Target

For more insight on analysts targets of NPCE, see our NPCE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.50 Average Broker Recommendation 1.3 (Strong Buy)

NPCE Stock Price Chart Interactive Chart >

Price chart for NPCE

NPCE Price/Volume Stats

Current price $1.61 52-week high $12.52
Prev. close $1.55 52-week low $1.38
Day low $1.60 Volume 42,900
Day high $1.90 Avg. volume 61,114
50-day MA $2.80 Dividend yield N/A
200-day MA $5.51 Market Cap 40.09M

NeuroPace, Inc. (NPCE) Company Bio


NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.


NPCE Latest News Stream


Event/Time News Detail
Loading, please wait...

NPCE Latest Social Stream


Loading social stream, please wait...

View Full NPCE Social Stream

Latest NPCE News From Around the Web

Below are the latest news stories about NEUROPACE INC that investors may wish to consider to help them evaluate NPCE as an investment opportunity.

NeuroPace Third Quarter 2022 Earnings: Beats Expectations

NeuroPace ( NASDAQ:NPCE ) Third Quarter 2022 Results Key Financial Results Revenue: US$11.2m (up 7.9% from 3Q 2021...

Yahoo | November 11, 2022

NeuroPace Reports Third Quarter 2022 Financial Results and Provides a Business Update

MOUNTAIN VIEW, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ending September 30, 2022. Recent Highlights Achieved total revenue of $11.2 million for the third quarter of 2022, representing growth of 8% compared to the third quarter of 2021 and 9% compared to the second quarter of 2022Achieved initial implant r

Yahoo | November 8, 2022

NeuroPace to Present at the 4th Annual Wolfe Research Healthcare Conference

MOUNTAIN VIEW, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 4th Annual Wolfe Research Healthcare Conference. Management is scheduled to present on Wednesday, November 16th at 2:40 p.m. Eastern Time. A live webcast of this event, as well as an archived recording, will be available on the “Investors” sectio

Yahoo | November 4, 2022

NeuroPace to Report Third Quarter 2022 Financial Results on November 8, 2022

MOUNTAIN VIEW, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter 2022 after market close on Tuesday, November 8, 2022. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time.

GlobeNewswire | October 25, 2022

Shareholders in NeuroPace (NASDAQ:NPCE) are in the red if they invested a year ago

As every investor would know, you don't hit a homerun every time you swing. But serious investors should think long and...

Yahoo | October 21, 2022

Read More 'NPCE' Stories Here

NPCE Price Returns

1-mo -42.50%
3-mo -58.82%
6-mo N/A
1-year -86.39%
3-year N/A
5-year N/A
YTD -84.03%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5725 seconds.